NCT00193219 - Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

July 31, 2010

Conditions

Colon Cancer

Interventions

DRUG

Bevacizumab

5 mg/kg IV

DRUG

Cetuximab

400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8

DRUG

5-fluorouracil

400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)

DRUG

Leucovorin

350 mg IV

DRUG

Oxaliplatin

85 mg/m2 IV

Trial Locations (10)

Center for Cancer and Blood Disorders, Bethesda

Tennessee Oncology, Nashville

Chattanooga Oncology and Hematology Associates, Chattanooga

Jackson Oncology Associates, Jackson

Consultants in Blood Disorders and Cancer, Louisville

Oncology Hematology Care, Cincinnati

Oncology Hematology Associates of SW Indiana, Evansville

St. Louis Cancer Care, Chesterfield

Methodist Cancer Center, Omaha

Mercy Hospital, Portland